All anthracyclines, including doxorubicin (DOXO), the most common and still indispensable drug, exhibit cardiotoxicity with inherent risk of irreversible cardiomyopathy leading to heart failure with reduced ejection fraction (HFrEF). Current pharmacological strategies are clearly less effective for this type of HFrEF, hence an urgent need for new therapeutic approaches. The prerequisite for success is thorough understanding of pathophysiology of this HFrEF form, which requires an appropriate animal model of the disease. The aim of this study was to comprehensively characterise a novel model of HF with cardiorenal syndrome, i.e. DOXO-induced HFrEF with nephrotic syndrome, in which DOXO was administered to Ren-2 transgenic rats (TGR) via five intravenous injections in a cumulative dose of 10 mg/kg of body weight (BW). Our analysis included survival, echocardiography, as well as histological examination of the heart and kidneys, blood pressure, but also a broad spectrum of biomarkers to evaluate cardiac remodelling, fibrosis, apoptosis, oxidative stress and more. We have shown that the new model adequately mimics the cardiac remodelling described as "eccentric chamber atrophy" and myocardial damage typical for DOXO-related cardiotoxicity, without major damage of the peritoneum, lungs and liver. This pattern corresponds well to a clinical situation of cancer patients receiving anthracyclines, where HF develops with some delay after the anticancer therapy. Therefore, this study may serve as a comprehensive reference for all types of research on DOXO-related cardiotoxicity, proving especially useful in the search for new therapeutic strategies.

Center for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Histology and Embryology Faculty of Medicine in Hradec Králové Hradec Králové Czech Republic

Department of Internal Medicine 1 Cardiology University Hospital Olomouc and Palacký University Olomouc Czech Republic

Department of Pharmaceutical Sciences College of Pharmacy University of Arkansas for Medical Sciences Little Rock AR USA

Department of Pharmacology Faculty of Medicine in Hradec Králové Charles University Hradec Králové Czech Republic

Laboratory of Developmental Cardiology Institute of Physiology of the Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 2022;4:19–37. PubMed PMC

Vuong JT, Stein-Merlob AF, Cheng RK, Yang EH. Novel therapeutics for anthracycline induced cardiotoxicity. Front Cardiovasc Med. 2022;9:863314. PubMed PMC

Leerink JM, de Baat EC, Feijen EAM, Bellersen L, van Dalen EC, Grotenhuis HB, et al. Cardiac disease in childhood cancer survivors: risk prediction, prevention, and surveillance: JACC cardiooncology state-of-the-art review. JACC CardioOncol 2020;2:363–78. PubMed PMC

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–79. PubMed

Mancilla TR, Iskra B, Aune GJ. Doxorubicin-induced cardiomyopathy in children. Compr Physiol. 2019;9:905–31. PubMed PMC

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8. PubMed

Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis. 2013;61:778–81. PubMed

Pereira Wde F, Brito-Melo GE, de Almeida CA, Moreira LL, Cordeiro CW, Carvalho TG, et al. The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update. Inflamm Res. 2015;64:287–301. PubMed

Grant MKO, Seelig DM, Sharkey LC, Choi WSV, Abdelgawad IY, Zordoky BN. Sexual dimorphism of acute doxorubicin-induced nephrotoxicity in C57Bl/6 mice. PLoS One. 2019;14:e0212486. PubMed PMC

Bansal N, Blanco JG, Sharma UC, Pokharel S, Shisler S, Lipshultz SE. Cardiovascular diseases in survivors of childhood cancer. Cancer Metastasis Rev. 2020;39:55–68. PubMed PMC

Kiaunyte S, Maske R, Kiudeliene R, Rutkauskiene G. Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology. Biomed Pharmacother. 2022;153:113316. PubMed

Faber J, Wingerter A, Neu MA, Henninger N, Eckerle S, Munzel T, et al. Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study. Eur Heart J. 2018;39:1555–62. PubMed

Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl J Med. 2006;355:1572–82. PubMed

Dixon SB, Liu Q, Chow EJ, Oeffinger KC, Nathan PC, Howell RM, et al. Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet. 2023;401:1447–57. PubMed PMC

Santos MLC, de Brito BB, da Silva FAF, Botelho A, de Melo FF. Nephrotoxicity in cancer treatment: an overview. World J Clin Oncol. 2020;11:190–204. PubMed PMC

Packer M, McMurray JJV. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail. 2021;23:882–94. PubMed PMC

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726. PubMed

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895–1032. PubMed

Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement From the American Heart Association. Circulation. 2019;139:e840–78. PubMed

Rosenzweig A. The growing importance of basic models of cardiovascular disease. Circ Res. 2022;130:1743–6. PubMed PMC

Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12:581–94. PubMed

Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, de Boer RA, et al. Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association. Circ Res. 2021;129:e21–34. PubMed PMC

Riehle C, Bauersachs J. Small animal models of heart failure. Cardiovasc Res. 2019;115:1838–49. PubMed PMC

Pilz PM, Ward JE, Chang WT, Kiss A, Bateh E, Jha A, et al. Large and small animal models of heart failure with reduced ejection fraction. Circ Res. 2022;130:1888–905. PubMed

Pokorna Z, Kollarova-Brazdova P, Lencova-Popelova O, Jirkovsky E, Kubes J, Mazurova Y, et al. Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up. Clin Sci (Lond). 2022;136:139–61. PubMed

Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, et al. Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22:292–310. PubMed

Refaie MMM, Shehata S, Ibrahim RA, Bayoumi AMA, Abdel-Gaber SA. Dose-dependent cardioprotective effect of hemin in doxorubicin-induced cardiotoxicity via Nrf-2/HO-1 and TLR-5/NF-kappaB/TNF-alpha signaling pathways. Cardiovasc Toxicol. 2021;21:1033–44. PubMed

Langheinrich M, Lee MA, Bohm M, Pinto YM, Ganten D, Paul M. The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens. 1996;9:506–12. PubMed

Moslehi J, Zhang Q, Moore KJ. Crosstalk between the heart and cancer: beyond drug toxicity. Circulation. 2020;142:684–7. PubMed PMC

Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19:9–42. PubMed

Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the cardio-oncology clinic. Heart Fail Clin. 2019;15:487–95. PubMed

Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biol. 2020;29:101394. PubMed PMC

Agostinucci K, Grant MKO, Seelig D, Yucel D, van Berlo J, Bartolomucci A, et al. Divergent cardiac effects of angiotensin ii and isoproterenol following juvenile exposure to doxorubicin. Front Cardiovasc Med. 2022;9:742193. PubMed PMC

Sobczuk P, Czerwinska M, Kleibert M, Cudnoch-Jedrzejewska A. Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Fail Rev. 2022;27:295–319. PubMed PMC

Kala P, Bartuskova H, Pitha J, Vanourkova Z, Kikerlova S, Jichova S, et al. Deleterious effects of hyperactivity of the renin-angiotensin system and hypertension on the course of chemotherapy-induced heart failure after doxorubicin administration: a study in Ren-2 transgenic rat. Int J Mol Sci. 2020;21:1–20. PubMed PMC

Jichova S, Gawrys O, Kompanowska-Jezierska E, Sadowski J, Melenovsky V, Hoskova L, et al. Kidney response to chemotherapy-induced heart failure: mRNA analysis in normotensive and ren-2 transgenic hypertensive rats. Int J Mol Sci. 2021;22:8475. PubMed PMC

Weinberg LE, Singal PK. Refractory heart failure and age-related differences in adriamycin-induced myocardial changes in rats. Can J Physiol Pharm. 1987;65:1957–65. PubMed

Nakahara T, Tanimoto T, Petrov AD, Ishikawa K, Strauss HW, Narula J. Rat model of cardiotoxic drug-induced cardiomyopathy. Methods Mol Biol. 2018;1816:221–32. PubMed

Jirkovsky E, Jirkovska A, Bavlovic-Piskackova H, Skalicka V, Pokorna Z, Karabanovich G, et al. Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation. Circ Heart Fail. 2021;14:e008209. PubMed

Kollarova-Brazdova P, Lencova-Popelova O, Karabanovich G, Kocurova-Lengvarska J, Kubes J, Vanova N, et al. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo. Clin Sci (Lond). 2021;135:1897–914. PubMed

Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M, et al. Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling. Circ Heart Fail. 2015;8:98–108. PubMed

Kala P, Gawrys O, Miklovic M, Vanourkova Z, Skaroupkova P, Jichova S, et al. Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension. J Hypertens. 2023;41:99–114. PubMed PMC

Kala P, Miklovic M, Jichova S, Skaroupkova P, Vanourkova Z, Maxova H, et al. Effects of epoxyeicosatrienoic acid-enhancing therapy on the course of congestive heart failure in angiotensin II-dependent rat hypertension: from mRNA analysis towards functional in vivo evaluation. Biomedicines. 2021;9:1053. PubMed PMC

Huskova Z, Kopkan L, Cervenkova L, Dolezelova S, Vanourkova Z, Skaroupkova P, et al. Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharm Physiol. 2016;43:438–49. PubMed

Sporkova A, Jichova S, Huskova Z, Kopkan L, Nishiyama A, Hwang SH, et al. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharm Physiol. 2014;41:1003–13. PubMed PMC

Huskova Z, Kramer HJ, Vanourkova Z, Cervenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J Hypertens. 2006;24:517–27. PubMed

Cervenka L, Melenovsky V, Huskova Z, Skaroupkova P, Nishiyama A, Sadowski J. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula. Clin Exp Pharm Physiol. 2015;42:795–807. PubMed

Kratky V, Kopkan L, Kikerlova S, Huskova Z, Taborsky M, Sadowski J, et al. The role of renal vascular reactivity in the development of renal dysfunction in compensated and decompensated congestive heart failure. Kidney Blood Press Res. 2018;43:1730–41. PubMed

Gawrys O, Huskova Z, Baranowska I, Walkowska A, Sadowski J, Kikerlova S, et al. Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. J Hypertens. 2020;38:1802–10. PubMed

Nakano Y, Hirano T, Uehara K, Nishibayashi S, Hattori K, Aihara M, et al. New rat model induced by anti-glomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progresses to end-stage renal failure. Pathol Int. 2008;58:361–70. PubMed

Dolezelova S, Jichova S, Huskova Z, Vojtiskova A, Kujal P, Hoskova L, et al. Progression of hypertension and kidney disease in aging fawn-hooded rats is mediated by enhanced influence of renin-angiotensin system and suppression of nitric oxide system and epoxyeicosanoids. Clin Exp Hypertens. 2016;38:644–51. PubMed

Vackova S, Kopkan L, Kikerlova S, Huskova Z, Sadowski J, Kompanowska-Jezierska E, et al. Pharmacological blockade of soluble epoxide hydrolase attenuates the progression of congestive heart failure combined with chronic kidney disease: insights from studies with fawn-hooded hypertensive rats. Front Pharm. 2019;10:18. PubMed PMC

Honetschlagerova Z, Skaroupkova P, Kikerlova S, Huskova Z, Maxova H, Melenovsky V, et al. Effects of renal sympathetic denervation on the course of congestive heart failure combined with chronic kidney disease: Insight from studies with fawn-hooded hypertensive rats with volume overload induced using aorto-caval fistula. Clin Exp Hypertens. 2021;43:522–35. PubMed

Kala P, Vanourkova Z, Skaroupkova P, Kompanowska-Jezierska E, Sadowski J, Walkowska A, et al. Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5/6 nephrectomized rats with aorto-caval fistula. Biomed Pharmacother. 2023;158:114157. PubMed

Gawrys O, Huskova Z, Skaroupkova P, Honetschlagerova Z, Vanourkova Z, Kikerlova S, et al. The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula. Naunyn Schmiedebergs Arch Pharm. 2023;396:3757–73. PubMed PMC

Peana D, Domeier TL. Cardiomyocyte Ca(2+) homeostasis as a therapeutic target in heart failure with reduced and preserved ejection fraction. Curr Opin Pharm. 2017;33:17–26. PubMed PMC

Tsikas D. Measurement of nitric oxide synthase activity in vivo and in vitro by gas chromatography-mass spectrometry. Methods Mol Biol. 2004;279:81–103. PubMed

Tsikas D. Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids. Free Radic Res. 2005;39:797–815. PubMed

Herman EH, Lipshultz SE, Rifai N, Zhang J, Papoian T, Yu ZX, et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998;58:195–7. PubMed

Adamcova M, Gersl V, Hrdina R, Melka M, Mazurova Y, Vavrova J, et al. Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol. 1999;125:268–74. PubMed

Bertinchant JP, Polge A, Juan JM, Oliva-Lauraire MC, Giuliani I, Marty-Double C, et al. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta. 2003;329:39–51. PubMed

Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. PubMed

Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N. The effects of doxorubicin on cardiac calcium homeostasis and contractile function. J Cardiol. 2022;80:125–32. PubMed

Renu K, Valsala Gopalakrishnan A. Deciphering the molecular mechanism during doxorubicin-mediated oxidative stress, apoptosis through Nrf2 and PGC-1alpha in a rat testicular milieu. Reprod Biol. 2019;19:22–37. PubMed

Holley AK, Dhar SK, St, Clair DK. Manganese superoxide dismutase versus p53: the mitochondrial center. Ann N. Y Acad Sci. 2010;1201:72–8. PubMed

Lencova-Popelova O, Jirkovsky E, Mazurova Y, Lenco J, Adamcova M, Simunek T, et al. Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. PLoS One. 2014;9:e96055. PubMed PMC

Vanvleet JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin-E and selenium as cardioprotectants. Am J Pathol. 1980;99:13–41. PubMed PMC

Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem. 2002;234-235:119–24. PubMed

Tadic M, Cuspidi C, Hering D, Venneri L, Danylenko O. The influence of chemotherapy on the right ventricle: did we forget something? Clin Cardiol. 2017;40:437–43. PubMed PMC

Sutariya B, Saraf M. alpha-asarone reduce proteinuria by restoring antioxidant enzymes activities and regulating necrosis factor kappaB signaling pathway in doxorubicin-induced nephrotic syndrome. Biomed Pharmacother. 2018;98:318–24. PubMed

Wang Y, Wang YP, Tay YC, Harris DC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000;58:1797–804. PubMed

Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest. 1982;46:16–23. PubMed

Kodner C. Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician. 2016;93:479–85. PubMed

Wang AJ, Zhang J, Xiao M, Wang S, Wang BJ, Guo Y, et al. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways. Cell Mol Life Sci. 2021;78:3105–25. PubMed PMC

Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK, et al. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol Mech Methods. 2013;23:337–45. PubMed

Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets. 2012;13:1207–14. PubMed

Sandner P, Follmann M, Becker-Pelster E, Hahn MG, Meier C, Freitas C, et al. Soluble GC stimulators and activators: Past, present and future. Br J Pharmacol. 2021;1–22. 10.1111/bph.15698. PubMed

Ataei Ataabadi E, Golshiri K, Juttner A, Krenning G, Danser AHJ, Roks AJM. Nitric oxide-cGMP signaling in hypertension: current and future options for pharmacotherapy. Hypertension. 2020;76:1055–68. PubMed

Krishnan SM, Kraehling JR, Eitner F, Benardeau A, Sandner P. The impact of the nitric oxide (NO)/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective. Int J Mol Sci. 2018;19:1712. PubMed PMC

Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883–93. PubMed

Sandner P, Vakalopoulos A, Hahn MG, Stasch JP, Follmann M. Soluble guanylate cyclase stimulators and their potential use: a patent review. Expert Opin Ther Pat. 2021;31:203–22. PubMed

Purohit R, Fritz BG, The J, Issaian A, Weichsel A, David CL, et al. YC-1 binding to the beta subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the alpha subunit. Biochemistry. 2014;53:101–14. PubMed PMC

Pontremoli R, Borghi C, Perrone Filardi P. Renal protection in chronic heart failure: focus on sacubitril/valsartan. Eur Heart J Cardiovasc Pharmacother. 2021;7:445–52. PubMed PMC

Cho H, Zhao XX, Lee S, Woo JS, Song MY, Cheng XW, et al. The sGC-cGMP signaling pathway as a potential therapeutic target in doxorubicin-induced heart failure: a narrative review. Am J Cardiovasc Drugs. 2022;22:117–25. PubMed

Sengupta P. The laboratory rat: relating its age with human’s. Int J Prev Med. 2013;4:624–30. PubMed PMC

Agoston DV. How to translate time? the temporal aspect of human and rodent biology. Front Neurol. 2017;8:92. PubMed PMC